SCHEMBL378960

SCHEMBL378960

CCOC(F)(F)CF.[B]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422185 0.97
SCHEMBL3141809 0.94
SCHEMBL3306265 0.76
SCHEMBL10264173 0.75
SCHEMBL10078901 0.74
SCHEMBL8371332 0.74
SCHEMBL4330955 0.74 ALDH1A1 (0.35)
SCHEMBL4317948 0.71
SCHEMBL6727225 0.71
SCHEMBL14983007 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3078034-B1 BATTERY SEPARATOR COMPRISING ELECTRONICALLY INSULATING LAYER AND BATTERY DEVICE UNIV MASSACHUSETTS (US) 2019-04-10 EP disclosed
US-9853269-B2 Electrical insulation layer and battery device SEKISUI CHEMICAL CO., LTD. (JP) 2017-12-26 US disclosed
US-20170331096-A1 ELECTRICAL INSULATION LAYER AND BATTERY DEVICE SEKISUI CHEMICAL CO., LTD. (JP) 2017-11-16 US disclosed
EP-3078034-A1 ELECTRICAL INSULATION LAYER AND BATTERY DEVICE The University of Massachusetts (US) 2016-10-12 EP disclosed
US-9284303-B2 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group JANSSEN PHARMACEUTICA N.V. (BE) 2016-03-15 US disclosed
US-20150155538-A1 ELECTRICAL INSULATION LAYER AND BATTERY DEVICE SEKISUI CHEMICAL CO., LTD. (JP) 2015-06-04 US disclosed
US-8778966-B2 Quinolinone derivatives as PARP and tank inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-07-15 US disclosed
US-20130324529-A1 BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP JANSSEN PHARMACEUTICA NV (BE) 2013-12-05 US disclosed
US-8524757-B2 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group JANSSEN PHARMACEUTICA NV (BE) 2013-09-03 US disclosed
US-20130018017-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS VIALARD JORGE EDUARDO (BE) 2013-01-17 US disclosed
US-8299256-B2 Quinolinone derivatives as PARP and TANK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-10-30 US disclosed
EP-2134691-B1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-01-25 EP disclosed
US-20100168065-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-01 US disclosed
EP-2081572-B1 BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP JANSSEN PHARMACEUTICA NV (BE) 2010-03-03 EP disclosed
US-20090312339-A1 BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP JANSSEN PHARMACEUTICA NV (BE) 2009-12-17 US disclosed
EP-2081572-A1 BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP JANSSEN PHARMACEUTICA N.V. (BE) 2009-07-29 EP disclosed
US-20080176862-A1 Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors ASTRAZENECA AB (SE) 2008-07-24 US disclosed
WO-2008003665-A1 BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP JANSSEN PHARMACEUTICA NV (BE) 2008-01-10 WO disclosed
US-20060065300-A1 Photoelectric conversion element, process for producing the same, light sensor and solar cell SONY DEUTSCHLAND GMBH (DE) 2006-03-30 US disclosed
US-6387906-B1 DERMATOPHYTES JANSSEN PHARMACEUTICA N.V. (BE) 2002-05-14 US disclosed